Drug Profile
AZD 5069
Alternative Names: AZD-5069Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antiasthmatics; Antineoplastics; Small molecules
- Mechanism of Action Interleukin 8B receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Coronary disorders; Head and neck cancer; Solid tumours
- Phase I/II Pancreatic cancer; Prostate cancer
- No development reported Bladder cancer; Non-small cell lung cancer
- Discontinued Asthma; Bronchiectasis; Chronic obstructive pulmonary disease
Most Recent Events
- 13 Jul 2023 Astellas terminates a phase I/II trial in Prostate cancer (Metastatic disease, Hormone refractory, Combination therapy) in Switzerland and United Kingdom (PO) due to discontinuation in production of IMP (NCT03177187) (EudraCT2016-003141-28)
- 29 Nov 2022 No development reported - Phase-II for Bladder cancer (Combination therapy) in USA (PO)
- 29 Nov 2022 No development reported - Phase-II for Non-small cell lung cancer (Combination therapy) in USA (PO)